2 U.S. lawmakers have disclosed 2 Aptevo Therapeutics Inc. trades under the STOCK Act — 1 buy and 1 sell between 2019 and 2026. Congress has been evenly split of APVO, and their disclosed buys are down 49.3% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of APVO, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-05-16 | Rohit Khanna | BUY | $15K–$50K | $4.77 | $2.42 2026-08-27 | -49.3% |
| 2019-06-24 | Steve Cohen | SELL | $470.99–$470.99 | $7712813.00 | $2.42 2026-08-27 | +100.0% exit |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
2 members of the U.S. House and Senate have disclosed Aptevo Therapeutics Inc. transactions under the STOCK Act — 1 purchase and 1 sale. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a APVO purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed APVO buys are down 49.3% versus the latest close of $2.42. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded APVO and how it performed.